Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | ($23.1M) | ($35.3M) | $20.3M | $8,926.0K | ($123.9M) | ($169.5M) | ($3,345.0K) | ($198.9M) | ($124.0M) | $432.3M | $419.4M | $652.8M | $974.0M | $1,034.5M | $1,812.0M | $2,000.4M | $2,003.5M | $6,529.4M | $4,424.8M | $3,667.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month Free Cash Flow is $3,377.6M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Regeneron Pharmaceuticals, Inc.'s Free Cash Flow growth was (26.7%). The average annual Free Cash Flow growth rates for Regeneron Pharmaceuticals, Inc. have been 18.5% over the past three years, 11.1% over the past five years.
Over the last year, Regeneron Pharmaceuticals, Inc.'s Free Cash Flow growth was (26.7%), which is lower than industry growth of (0.1%). It indicates that Regeneron Pharmaceuticals, Inc.'s Free Cash Flow growth is Bad.